Journal of Clinical and Aesthetic Dermatology

Psoriasis and Cutaneous Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/729153

Contents of this Issue

Navigation

Page 12 of 35

U pdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting [ S E P T E M B E R 2 0 1 6 • V O L U M E 9 • N U M B E R 9 ] S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y S 9 TABLE 2. Number needed to treat (NNT) of main drugs used to treat psoriasis (the NNT values are the number needed to treat in order to achieve a PASI 75 score as a primary endpoint of a clinical trial) DRUG THERAPY (%) PLACEBO (%) THERAPEUTIC E FFECT P RIMARY ENDPOINT (WEEKS) NNT COMMENT Alefacept 21 5 16 14 6.3 15mg IM Methotrexate 35.5 18.9 16.6 12 6.0 CHAMPION Apremilast 33.1 5.3 27.8 16 3.6 ESTEEM 1 E falizumab 3 9 2 .4 3 6.6 1 2 2 .7 1 mg/kg/wk Etanercept 49 4 45 12 2.2 50mg biw Adalimumab 71 6.5 74.5 16 1.6 40mg EOW Ustekinumab 66 3 63 12 1.6 90mg Infliximab 75.5 1.9 73.6 10 1.4 5mg/kg IV Secukinumab 81.6 4.5 77.1 12 1.3 300mg Ixekizumab 89.1 3.9 85.2 12 1.2 80mg TABLE 3. Main drugs used to treat psoriasis, number needed to treat (NNT) required to achieve PASI 90 at primary endpoint DRUG THERAPY (%) PLACEBO (%) THERAPEUTIC EFFECT PRIMARY ENDPOINT (WEEKS) NNT COMMENT Methotrexate 13.6 11.3 2.3 12 43.5 CHAMPION Etanercept 22 1 21 12 4.8 50mg biw Adalimumab 45 2 43 16 2.3 40mg EOW Ustekinumab 36.7 2 34.7 12 2.9 90mg Infliximab 45.2 0.5 44.7 10 2.2 5mg/kg IV Secukinumab 59.2 1.2 58 12 1.7 300mg Ixekizumab 70.9 0.5 70.4 12 1.4 80mg TABLE 4. Main drugs used to treat psoriasis, number needed to treat (NNT) required to achieve PASI 100 at primary endpoint DRUG THERAPY (%) PLACEBO (%) THERAPEUTIC EFFECT PRIMARY ENDPOINT (WEEKS) NNT COMMENT Etanercept 4.3 0 4.3 12 23.3 50mg biw (Fixture) Adalimumab 29 1 18 16 5.3 40mg EOW Ustekinumab 10.9 0 10.9 12 9.2 90mg Infliximab 25.6 1 24.6 10 4.1 5mg/kg IV Secukinumab 28.6 0.8 27.8 12 3.6 300mg Ixekizumab 35.3 0 35.3 12 2.8 80mg Q2W

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Psoriasis and Cutaneous Supplement 2016